Clinical trials: Cardiac Thrombus
Atrial Fibrillation, Left Atrial Appendage Thrombosis
Resolution of Thrombi in Left Atrial Appendage With Edoxaban
Non-valvular (NV) atrial fibrillation (AF) increases the risk of stroke by approximately fivefold. The atrial thrombi associated with AF are seen within the left atrial appendage (LAA) in most cases (> 90%).
- Trial name
- REFLEX (NCT03840291)
- Testing
- Edoxaban
- Where
- 12 sites in South Korea
- Volunteers
- 36 people
- Sponsor
- Keimyung University Dongsan Medical Center
Arthritis of Knee, Arthritis of Hip
Comparison of the Diagnosis Time of VET and SCL in Patients With Intraoperative Coagulopathy
The present study is a prospective, multi-center observational trial comparing the times taken to diagnose coagulopathies using point-of-care (POC) viscoelastic tests or standard central laboratory tests (SCL tests) in patients…
- Conditions
- Arthritis of Knee, Arthritis of Hip, Spine, Prostate Cancer
- Trial name
- NCT06637943
- Testing
- SCL tests, POC viscoelastic tests
- Where
- 4 sites in South Korea
- Volunteers
- 210 people
- Sponsor
- Konkuk University Medical Center
Atrial Fibrillation
A Study Evaluating Safety and Tolerability of YM150 Compared to Warfarin in Subjects With Atrial Fibrillation
The purpose of this study is to investigate the optimal daily dose and dose regimen of YM150 in subjects with non-valvular atrial fibrillation (NVAF), primarily based on safety and tolerability data.
- Trial name
- OPAL-2 (NCT00938730)
- Testing
- YM150, Warfarin
- Where
- 170 sites in Australia, Austria and 21 more
- Volunteers
- 1,280 people
- Sponsor
- Astellas Pharma Inc
Atrial Fibrillation, Thrombosis
Association of Genetic Polymorphisms With Atrial Fibrosis and Thrombogenic Substrate in Patients With Non-valvular Atrial Fibrillation
Atrial fibrillation (AF) is the most frequently encountered cardiac arrhythmia. Emerging data suggests that common genetic variants are associated with the development of AF.
- Conditions
- Atrial Fibrillation, Thrombosis, Stroke, Genetic Predisposition
- Trial name
- ANATOLI-AF (NCT03560219)
- Testing
- Biomarkers, Cardiac Magnetic Resonance Imaging, Echocardiography, Flow Mediated Dilatation, Genetic Analysis
- Volunteers
- 225 people
- Sponsor
- Memorial Ankara Hospital
ST-segment Elevation Myocardial Infarction, Thrombus
CompariSon of Manual Aspiration With Rheolytic Thrombectomy in Patients Undergoing Primary PCI. The SMART-PCI Trial
To compare rheolytic thrombectomy (RT) with manual thrombus aspiration (MTA) in patients with acute ST-segment elevation myocardial infarction (STEMI) undergoing primary PCI.
- Trial name
- SMART (NCT01281033)
- Testing
- Manual Thrombectomy, AngioJet Rheolytic Thrombectomy (RT) System
- Where
- Italy
- Volunteers
- 80 people
- Sponsor
- Careggi Hospital
Atrial Fibrillation, Recurrent Venous Thromboembolism
Real-life Clinical Outcomes of Direct Oral Anticoagulants (MACACOD)
MACACOD is a clinical record in the usual clinical practice of direct oral anticoagulants (dabigatran, rivaroxaban, apixaban and edoxaban).
- Trial name
- MACACOD (NCT04042155)
- Testing
- dabigatran, rivaroxaban, apixaban or edoxaban
- Where
- Spain
- Volunteers
- 1,600 people
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Aortic Stenosis
Biological Factors Associated With Subclinical Valvular Thrombosis
A prospective, multicentric cohort study including 166 patients with symptomatic aortic stenosis treated with transcatheter aortic valve implantation (TAVI).
- Trial name
- START (NCT03847948)
- Testing
- CT SCAN
- Where
- 2 sites in Spain
- Volunteers
- 166 people
- Sponsor
- Hospital San Carlos, Madrid
Atrial Fibrillation (AF), Atrial Fibrillation (Prevention of Stroke)
Stroke Risk Assessment and Markers of Blood Clotting in Patients With Newly Diagnosed Non-valvular Atrial Fibrillation (NVAF), Who Have Not Received Oral Anticoagulation Therapy (OAC-therapy) Prior to Inclusion
Background: Atrial fibrillation (AF) is the most common heart rhythm disorder worldwide. Globally, there are 37.5 million people with AF.
- Conditions
- Atrial Fibrillation (AF), Atrial Fibrillation (Prevention of Stroke), Atrial Fibrillation New Onset, Non Valvular Atrial Fibrillation
- Trial name
- BIO-AF (NCT06949319)
- Where
- Denmark
- Volunteers
- 150 people
- Sponsor
- Nedim Tojaga
Ischemic Stroke, Atrial Fibrillation
Optimal Antithrombotic Therapy in Ischemic Stroke Patients with Non-Valvular Atrial Fibrillation and Atherothrombosis
The Purpose of this open-label randomized controlled multicenter trial is to evaluate the efficacy and safety of mono-drug therapy with oral anticoagulant compared to combination therapy with antiplatelet drug, in ischemic stroke…
- Conditions
- Ischemic Stroke, Atrial Fibrillation, Atherothrombosis
- Trial name
- ATIS-NVAF (NCT03062319)
- Testing
- Oral Anticoagulant, Antiplatelet Drug
- Where
- Japan
- Volunteers
- 321 people
- Sponsor
- National Hospital Organization Osaka National Hospital
Atrial Fibrillation, Intracardiac Thrombus
Response of Intracardiac Thrombus to Anticoagulants in Patients With Non-valvular Atrial Fibrillation (LYSIS)
This study aims to analyze changes in the immune status, metabolic status, and host microbiome community structure in non-valvular atrial fibrillation patients with intracardiac thrombus.
- Trial name
- LYSIS (NCT06141538)
- Testing
- Observational; No Interventions were given.
- Where
- China
- Volunteers
- 500 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Coronary Artery Disease, Clopidogrel Resistance
The Study of CYP2C19 Genotype-Guided Clopidogrel Treatment Models
The study purposed to learn how clopidogrel-based antiplatelet treatment for preventing adverse cardiovascular events after ePCI works in chronic coronary artery disease when guided by personal genetic characteristics for drug…
- Conditions
- Coronary Artery Disease, Clopidogrel Resistance, Coronary Thrombosis, Adverse Cardiac Events
- Trial name
- NCT06665919
- Testing
- CYP2C19 Genotype-Guided Clopidogrel Treatment, CYP2C19 Genotype Guided Antiplatelet Treatment Alternative to Clopidogrel, The Conventional Clopidogrel Treatment
- Where
- 4 sites in Georgia
- Volunteers
- 283 people
- Sponsor
- Vistamedi Ltd.
Anticoagulant Therapy
In Vitro Diagnostic Test for DOAC in Urine
This trial is conducted to assess the performance and handling of the in vitro diagnostic (IVD) device for oral direct factor Xa and thrombin inhibitors from urine samples of patients on treatment with direct oral anticoagulants…
- Trial name
- PADOASU (NCT03182829)
- Testing
- DOAC Dipstick
- Where
- 18 sites in Germany
- Volunteers
- 880 people
- Sponsor
- Doasense GmbH
Thrombosis
Anticoagulation Regiments in Patients With Prosthetic Heart Valve Thrombosis
Prosthetic valve thrombosis is a serious complication with high mortality and morbidity. However, the best anticoagulant treatment strategies for patients with prosthetic heart valve thrombosis have not been fully known.
- Trial name
- NCT02240953
- Testing
- Warfarin, Warfarin + ASA 100 mg + PPI, Warfarin + ASA 300 mg + PPI
- Where
- Turkey (Türkiye)
- Volunteers
- 180 people
- Sponsor
- Kartal Kosuyolu Yuksek Ihtisas Education and Research Hospital
Coronary Restenosis
Clinical Evaluation of Patients With Everolimus-eluting Stent Xience V® Implanted in the Treatment of Restenosis in Non-coated Metallic Stent (BMS In-stent Restenosis) During a 2 Year Clinical Follow-up Period
Interventional, prospective, non-randomized, non-comparative, open and multicentric study of patients with everolimus-eluting stent " Xience V® " implanted in the treatment of restenosis in non-coated metallic stent (BMS in-stent…
- Trial name
- XERES (NCT00882219)
- Testing
- Xience V®
- Where
- France
- Volunteers
- 102 people
- Sponsor
- Abbott Medical Devices
Heart Attack, Cardiac Arrest
Systematic Assessment and Targeted Improvement of Services Following Yearlong Surgical Outcomes Surveys
Based on limited published epidemiological data, up to an alarming 1 in 50 surgical inpatients die within 30 postoperative days.
- Conditions
- Heart Attack, Cardiac Arrest, Congestive Heart Failure, Atrial Fibrillation
- Trial name
- SATISFY-SOS (NCT02032030)
- Where
- United States
- Volunteers
- 73,952 people
- Sponsor
- Washington University School of Medicine
Congenital Heart Disease, Single-ventricle
Extracellular Vesicle Micro RNA Profiling in Congenital Heart Disease: Fetal-Maternal Regulation in Neonatal Thrombosis
Newborns with congenital heart disease (CHD) are at increased risk of developing postpartum and postoperative blood clots after cardiac surgery.
- Conditions
- Congenital Heart Disease, Single-ventricle, Thrombosis
- Trial name
- EVmiRNA (NCT06434207)
- Testing
- Collecting discarded blood samples
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Boston Children's Hospital
Stent Thrombosis, Acute Coronary Syndrome
Stent Thrombosis In Acute Coronary Syndromes
The purpose of this study is to better understand what treatment methods result in the best outcomes for patients who have heart attacks due to blood clots forming within stents.
- Trial name
- NCT00931502
- Where
- United States
- Volunteers
- 800 people
- Sponsor
- University of California, Davis
Atrial Fibrillation, Deep Vein Thrombosis
Predictors of Anticoagulation Control on Warfarin Therapy
The goal of this research study is to develop better dosing of anticoagulation medication in both Caucasian and African Americans through analysis of various genetic factors.
- Conditions
- Atrial Fibrillation, Deep Vein Thrombosis, Heart Valve Replacement
- Trial name
- NCT00905177
- Where
- 2 sites in United States
- Volunteers
- 687 people
- Sponsor
- University of Pennsylvania
Atrial Fibrillation, Deep Vein Thrombosis
Weekly Monitoring Strategy of Capillary INR Versus Monthly Monitoring Strategy of Venous INR in Elderly Patients in a Nursing Home.
This primary care study aims to compare the "time in therapeutic range" (TTR) of two strategies for monitoring the international normalized ratio (INR) over 6 months in nursing homes.
- Conditions
- Atrial Fibrillation, Deep Vein Thrombosis, Stroke
- Trial name
- INR-CAP (NCT05561244)
- Testing
- Weekly monitoring using the capillary International Normalised Ratio strategy
- Where
- 33 sites in France
- Volunteers
- 45 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Acute Myocardial Infarction
Nobori And Uncoated Stent In Coronary Attack
Drug-eluting stents reduce rates of restenosis and reintervention, as compared with uncoated stents. Data are limited regarding the safety and efficacy of Nobori (Biolimus A9 Eluting Stent) in primary percutaneous coronary…
- Trial name
- NCT01401036
- Testing
- Biolimus A9 eluting stents, uncoated stent
- Where
- 50 sites in Japan
- Volunteers
- 1,537 people
- Sponsor
- Shigeru Saito